(1) The majority of clinical studies with these agents focus on surrogate markers of cardiovascular disease such as blood pressure reduction, regression of left ventricular hypertrophy or reduction in proteinuria. (2) Studies that examined changes in proteinuria demonstrate consistent differences between dihydropyridine CCAs (amlodipine-like agents) and non-dihydropyridine CCAs (verapamil, diltiazem). Specifically, dihydropyridine CCAs do not reduce proteinuria when examined in studies of у2 years duration. 4 Conversely, in studies of similar duration with non-dihydropyridine CCAs, a consistent reduction in proteinuria is noted. 5, 6 (3) Lastly, in double-blind, placebo-controlled, secondary prevention trials of cardiovascular events, dihydropyridine CCAs failed to demonstrate a reduction in ischaemic coronary events in a population of patients with either heart failure or hypertension. 7, 8 Conversely, dihydropyridine CCAs, when used in concert with ACE inhibitors, demonstrate a reduction in cardiovascular mortality among patients with heart failure from non-ischaemic causes. 8 Another possible exception to this apparent lack of benefit by dihydropyridine CCAs on cardiovascular event reduction, is the SYST-EUR Trial. This trial demonstrated reductions in cardiovascular events and mortality in a group of elderly patients without heart failure or renal disease randomised to a dihydropyridine CCA. 9 However, while there was a reduction in myocardial infarcation it did not achieve statistical significance by itself. 9 In contrast to this inconsistent outcome of cardiovascular events with dihydropyridine CCAs, two separate post-myocardial infarction trials with non-dihydropyridine CCAs demonstrate a clear reduction in ischaemic cardiovscular events and mortality in patients who did not have heart failure. 10, 11 This is further suported by a recent pilot study of 100 patients with heart failure given a non-dihydropyridine CCA along with an ACE inhibitor. 12 Taken together, these observations clearly indicate that in patients with pre-existing cardiovascular or renal disease, dihydropyridine CCAs, when used without an ACE inhibitor, may reduce arterial pressure but fail to offer protection from the natural history of cardiovascular or renal disease. 12 It is clear, however, from smaller clinical studies as well as previously mentioned trials that both reductions in cardiovascular events as well as renal disease progression is observed when blood pressure reduction occurs with non-dihydropyridine CCAs. 5, 6, [10] [11] [12] The first true clinical trial in diabetic nephropathy, however, that provides evidence for a clear difference between dihydropyridine CCAs and ACE inhibitors comes from the recently published Appropriate Blood Pressure Control and Diabetes Trial (ABCD Trial). 13 This trial has, as its primary objective, to determine the relative effects of moderate and intensive blood pressure control on the change in creatinine clearance among both normotensive and hypertensive patients all of whom had type 2 diabetes.
The trial design is randomised double-blind placebo-controlled and illustrated in Figure 1 . Sec- ondary end-points of the trial included the effects of intensive vs moderate blood pressure control on the incidence of cardiovascular effects, retinopathy, neuropathy, proteinuria, and left ventricular hypertrophy. While the renal trial will be completed in June of 1998, the number of fatal and non-fatal cardiovascular events in the hypertensive group mandated stopping the trial early and switching the participants to ACE inhibitors. These findings are predicated on the fact that after 67 months of followup, there was a significant difference in the rate of cardiovascular events between the subgroups of hypertensive patients treated with the two study drugs, ie, nisoldipine vs enalapril. The results indicate a five-fold higher incidence of fatal and nonfatal myocardial infarction randomised to nisoldipine vs the ACE inhibitor. Moreover, there were twice as many deaths from cardiovascular causes in the group receiving nisoldipine vs enalapril. Interestingly, three out of the five patients (60%) in the enalapril group and 23 of the 25 (92%) in the nisoldipine group did not have a history of cardiovascular events, ie, myocardial infarction. Therefore, it could be argued, albeit weakly, that dihydropyridine CCAs fail to protect from the development of myocardial infarction in spite of blood pressure control in a high-risk group of patients. These results are similar to those found in other clinical trials published earlier. 7, 8 These cardiovascular outcomes could not be explained by baseline lipid profiles, since they were significantly worse in the group randomised to enalapril vs nisoldipine nor could they be explained by differences in blood pressure control or glucose control between the two groups. Another factor that may have played a role is that a significantly higher number of patients were receiving a beta-blocker and/or diuretic in the group randomised to enalapril vs the ACE inhibitor. However, when this was taken into account statistically, it did not explain the significant difference in cardiovascular events between the two groups.
These data with dihydropyridine CCAs and their failure to protect against cardiovascular events in high-risk populations are further bolstered by the recently completed Fosinopril and Amlodipine Cardiac Events Trial (FACET).
14 In this open labelled study that randomised participants to either an ACE inhibitor or a long acting dihydropyridine CCA, the cardiac event rate was approximately double in the amlodipine alone group vs the ACE inhibitor group. Moreover, the trial was stopped early due to this trend.
These data, taken together with other smaller studies, suggest that dihydropyridine CCAs lower blood pressure, but regardless of their duration of action, fail to offer protection against development of cardiovascular events in patients with established diabetic nephropathy. The reasons for this are unclear. However, the degree of disease progression at the time of intervention may be a key-determining factor. While it is clear that people with pre-existing renal disease, diabetes, and hypertension may not gain benefits from blood pressure reduction with dihydropyridine CCAs, this does not appear to be the case in healthier elderly patients with hypertension alone or with diabetes in the absence of renal insufficiency. 8, 15 Likewise, other very large scale trials such as the ALLHAT Trial 16 and the Hypertension Optimal Treatment (HOT) Trial, 17 each with a dihydropyridine CCA arm, have not been stopped due to unusually high cardiovascular event rates.
In conclusion, the available data as well as the current recommendations of the Joint Committe Report on the Diagnosis, Prevention and Treatment of Hypertension, JNC VI, mandate that an ACE inhibitor be included in the 'anti-hypertensive cocktail' of medications used to lower blood pressure in patients with either diabetic nephropathy, renal insufficiency or heart failure. 18 Moreover, dihydro-pyridine CCAs should not be utilised without the concomitant use of an ACE inhibitor since, alone they do not reduce cardiovascular events among those with diabetic nephropathy. However, in patients with diabetic nephropathy, non-dihydropyridine CCAs seem to reduce cardiovascular events and mortality and perhaps renal disease progression. [4] [5] 19, 20 This benefit may be accentuated when non-dihydropyridine CCAs are used in concert with ACE inhibitors. 12, 19, 20 Thus, these discrepancies in cardiovascular outcomes of various studies including the ABCD Trial should remind us to be cautious with data extrapolation from a population with established renal disease from diabetes to those with an absence of end organ failure and hypertension alone.
